Immunology Biosimilars Market Research 2024-2030, Profiles of Key Players - F. Hoffmann-La Roche, Merck, Eli Lily,. Pfizer, Novartis, Teva, Boehringer Ingelheim, Celltrion, Samsungbioepis,...
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Disease, Other Indications), By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering. The Global Immunology Biosimilars market showcased growth at a CAGR of 17.92% during 2020-2023. The market was valued at USD 8.03 billion in 2023 which is expected to reach USD 16.22 billion in 2030. This report provides an analysis for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030. The global Immunology Biosimilars market is expected to witness strong growth during the forecast period, driven by multiple factors. A key factor is the rising incidence of chronic immunological conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, which is fueling the demand for cost-effective treatment solutions. As affordable alternatives to branded biologics, biosimilars are gaining significant traction, especially in regions with well-establis
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck to Participate in the Jefferies London Healthcare ConferenceBusiness Wire
- Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd. [Yahoo! Finance]Yahoo! Finance
- Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.Business Wire
- Kimberly-Clark Elects Joseph Romanelli to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Microbiotica Announces First Patient Dosed in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 10/31/24 - Beat
MRK
Sec Filings
- 11/6/24 - Form 10-Q
- 11/4/24 - Form 25-NSE
- 10/31/24 - Form 8-K
- MRK's page on the SEC website